Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Feasibility Phase I Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

NCT06066138 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT06066138
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06066138 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Feasibility Phase I Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Recruiting
Start date
November 4, 2025
Completion date
January 31, 2028
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced alveolar soft part sarcoma, locally advanced hepatocellular carcinoma, locally advanced melanoma, locally advanced non small cell lung cancer, locally advanced small cell lung cancer, metastatic alveolar soft part sarcoma, metastatic hepatocellular carcinoma, metastatic melanoma, metastatic non small cell lung cancer, metastatic small cell lung cancer